Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7568282 biological properties and safety study in healthy participants and participants with Parkinson's disease
NL-OMON61012Phase 1Recruiting
- Sponsor
- Roche
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of RO7568282 in Parkinson's disease (PD) (2 arms), sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Sep 2024; status: recruiting.
02
Drugs
RO7568282
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON61012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61012.